Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
Date:5/6/2008

e rapid onset of action."

"Reaching the patient enrollment target in our Phase III clinical trial of Omigard for the prevention of catheter-related infections is a major milestone in our clinical development program for this product candidate," stated James Breitmeyer, M.D., Ph.D., Executive Vice President, Development and Chief Medical Officer of Cadence. "If approved, we believe that Omigard will address a rapidly growing need for more effective ways to lower hospital acquired infection rates, including the dangerous and costly complications from infections related to intravascular catheters."

Cadence's second clinical trial of Acetavance for the treatment of fever in adults, designated Study 303, was a Phase III, randomized, double-blind, double-dummy, single-dose study of intravenous acetaminophen (1 gram) compared to oral acetaminophen (1 gram) for the treatment of fever in 81 adult volunteers with experimentally-induced fever. In this study, a statistically significant difference in favor of Acetavance was observed compared to oral acetaminophen for the primary efficacy endpoint of WSTD2 (the weighted sum of temperature differences over two hours) (p< 0.01). The mean temperature scores for patients in the Acetavance-treated group were significantly lower as early as 15 minutes after the study drug was administered. The peak temperature observed in the Acetavance group of patients was also significantly lower. Acetavance was very well tolerated, including no treatment-emergent serious adverse events or treatment-emergent hepatic adverse events.

Cadence's confirmatory Phase III clinical trial of Omigard (omiganan pentahydrochloride 1% gel), known as the Central Line Infection Reduction Study, or CLIRS, is a randomized, evaluator-blinded study in hospitalized patients whose medical condition requires a short-term central venous catheter. The primary objective of CLIRS is to evaluate the efficacy and safety of Omigard compared to 10% povidone-
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
3. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
4. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
5. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
6. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
7. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
8. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
9. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
10. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
11. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Developed by AstraZeneca ... is an important drug for the treatment of ... 2000, quetiapine was listed in the Catalogue of ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... report to their offering. Developed by ... selective prostaglandin receptor agonist which effectively reduces intraocular ... by FDA, latanoprost (under the trade name of ...
(Date:8/28/2015)... KONG , August 28, 2015 ... in collaboration with one of the leading academics in ... (current world record holder in life extension for model ... insights into biology of aging and age-related diseases, primarily, around ... The work has just been published as "Stability analysis of ...
Breaking Medicine Technology:China Quetiapine Market Investigation Report 2010-2019 2China Latanoprost Market Investigation Report 2015-2019 2Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3
... At the end of 2009, the vaccine industry raised ... business media were occupied by various kinds of news ... successfully landed on the Nasdaq, then Simcere, a pharmaceutical ... announced a 50.8% stake in Ealong Biotech and took ...
... EAST HANOVER, N.J., Oct. 16 Novartis announced today ... safety profile of once-yearly Reclast® (zoledronic acid) injection in ... 1,200 women was presented this weekend at the annual ... Research (ASBMR) in Toronto, ON, Canada. The ...
Cached Medicine Technology:Vaccine Leaders All Over the World Talking About China Vaccine Opportunities at VacChina 2010 -- the No.1 China Focused Vaccine Partnering Forum 2Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 2Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 3Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 4Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 5Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 6
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... Brands like ... with zero standard shipping costs. , “Before, a threshold of $49.00 was required ... select brands and items qualify for free standard shipping for customers regardless of the ...
(Date:8/29/2015)... , ... August 29, 2015 , ... The popular television ... Earl Jones, recently announced that it will be devoting an entire short segment to ... millions of people around the globe on a daily basis, but recent advancements in ...
(Date:8/28/2015)... Columbus, Ohio (PRWEB) , ... August 28, 2015 ... ... Saturday’s Imagine No Malaria Day at the Zoo to celebrate children helping children, ... people and their congregations throughout West Ohio have contributed to the United Methodist ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Understanding the FDA’s Position and Best Practices for Compliance, **Presented by FDAnews ... This workshop, chaired by internationally renowned expert Fubin Wu, has been specifically ...
(Date:8/28/2015)... ... 28, 2015 , ... Saint Petersburg, FL —Pocket Protein™, a ... carbs, sugar, gluten, lactose or caffeine in a convenient 2 oz. pouch that ... Editor’s Choice Awards. , Five consumer packaged goods (CPG) products were selected by ...
Breaking Medicine News(10 mins):Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3
... panic among poultry farmers in Uttar Pradesh after reports got ... Aligarh Farm. Official confirmation is still awaited. ,UP ... are being given antibiotics and vitamins. Samples from the dead ... a lab in Izzatnagar and the Veterinary University, Mathura, although ...
... manufactured TGN-1412, has now admitted that the drug had ... of the six who were admitted to the intensive ... drug administration are recovering, according to official reports. ... Northwick Park Hospital in Harrow, London. Two of the ...
... Australian government has recently started, ads campaigning the need for ... a couch potato all day long//, but the mothers of ... are so. In a medical survey conducted by the government ... or chubby the mothers failed to accept it saying that ...
... of nine more cases of the deadly H5N1 strain of ... by the country's veterinary authorities, two days after nine tufted ... that the ducks were found in the South of the ... Aeroe. ,Authorities in Denmark also confirmed that following ...
... is 24-years-old is one among the first British patients to ... a special device is placed to help her overcome stammering. ... Lieckfeldt said the device would be fitted in her inner ... research that stammerers are helped by speaking in unison with ...
... the cards that will be a landmark on the EM ... project which will come up// in two phases that will ... cancer patients. Bangalore and Ahmedabad will follow suit with ... Foundation chairman, had a meeting with the chief minister to ...
Cached Medicine News:Health News:Drug Company Admits Knowledge Of Side Effects In Monkeys 2
Hydrodissection / Aspiration Cannula, 25 g. Straight with U-tip. U-shaped tip allows aspiration and irrigation at the 12 o'clock position. Overall length 18 mm. 5/box....
Hydrodissection / Aspiration Cannula, 25 g. Angled with left hook. 10 mm angled shaft with 2.5 mm left hook tip. Overall length 20 mm. 5/box....
Retinal Hydrodissection Cannula. 20 gauge shaft tapers to 41 gauge I.D. flexible tip. Packaged sterile. 5/Box....
Posterior Capsule Polisher, 23 g., 30 angle small gauge with roughened tip, open end port. Overall length 16 mm. 5/box....
Medicine Products: